3D Tissue Models

Cancer Biology: GlaxoSmithKline

Total Score People Score Events Score
41 38 31
Date Event Presentation Speakers
April 6, 2013 AACR Annual Meetings From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 2: Targeting Epigenetics: An Epicenter of Oncology Drug Discovery? Chairperson: Ho Man Chan, Novartis Institutes for BioMedical Research, Cambridge, MA Dashyant Dhanak
From Chemistry to the Clinic: Pathways for Drug Discovery and Development, Part 4: Oncology Drug Discovery and Development: Combination Therapies Chairperson: Tona M. Gilmer, GlaxoSmithKline, Research Triangle Park, NC Tona M Gilmer, Axel Hoos
May 23, 2012 Biomarkers World Europe 2012 Preclinical predictive biomarker discovery for MEK inhibitor in oncology Yan Degenhardt
Design strategies for success in early phase trials Nigel Dallow
Panel: Developing stratified medicine through partnerships John Whittaker
February 20, 2012 Advances and Progress in Drug Design Molecular obesity, potency and other addictions in medicinal chemistry Mike Hann,
November 12, 2011 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics BRAF and MEK inhibition in melanoma Tona M Gilmer
June 27, 2011 RNAi, miRNA & siRNA Computational support of potential RNAi therapeutics Paul Wilson
March 23, 2011 Accelerating Patient Recruitment & Retention in Clinical Trials Predictive patient recruitment modelling Vladimir Anisimov
March 7, 2011 Imaging in Cancer Drug Development The role of PET in drug development Jan Passchier
February 24, 2011 Targeting P13K / mTOR Signaling in Cancer GSK2126458: A potent inhibitor of PI3K and mTOR Richard WOOSTER
February 12, 2011 Cancer Control by Tumor Suppressors and Immune Effectors (J8) Cancer Vaccines: Prophylaxy or Therapy | Development of the MAGE-A3 ASCI: From Tumor Specificity to Predictive Biomarkers Vincent G Brichard
August 10, 2010 The International Quantitative Imaging Cytometry Centers of Excellence Provide a Forum for Educational and Training Programs in Quantitative Imaging Cytometry, with a Specific Focus on Solid-Phase Laser Scanning Imaging Cytometry Workshop II | Quantitative Assessment of Pancreatic Islets David Krull
May 10, 2010 The New Science of Ageing Drug discovery for a broadspectrum, preventative medicine for ageing P Vallance
September 23, 2009 TRACK 4: Bridging Silos in Biomarker Development : Third Annual Biomarker Data Analysis An Effective Framework for Omic Data Analysis Jie J. Cheng
June 9, 2009 Cell and Tissue-Based Assays for HTS Novel Assays and New Technologies Kalpana Patel
Table Six: Novel Assays, New Technologies and their Applications Kalpana Patel
June 9, 2009 Third Annual Cardiotoxicity and Drug Safety Use of Cardiac Troponin Measurements in Drug Development For the Detection of Cardiotoxicity John K. Finkle
June 9, 2009 Translating Genomic Knowledge Chairperson’s Remarks Eric C Lai
Panel Discussion – Successful Data Flow in Translation Discovery Research Eric C Lai
Integrating Pharmacogenetics Throughout the Pharma Value Chain Daniel K. Burns
June 8, 2009 Genotyping Tools KEYNOTE PRESENTATION Allen Roses
December 2, 2008 4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development 1: The synthesis and design of PET radiotracers Anthony Gee,
December 2, 2008 Vaccines Europe 1: Advances with adjuvants that enhance the quality of the immune response Nathalie Garcon,
1: Experiences with animal models for pre-clinical testing of therapeutic vaccines / translating animal studies into man Catherine Gérard,
December 2, 2008 4th Annual Global Imaging Summit -The Application of Molecular and Cellular Imaging in Drug Discovery & Optimising Imaging Techniques in Preclinical and Clinical Drug Development 2 : Opening remarks from the Chairperson Phil Murphy,
2 : PET for managing the gap between laboratory and man - A Drug Company Perspective Anthony Gee,
2 : Panel Debate: How translatable is preclinical and clinical imaging? Phil Murphy,
2 : Closing remarks from the chairperson and end of conference day one Phil Murphy,
2 : Opening remarks from the Chairperson Phil Murphy,
2 : Exploiting the benefits of DCE MRI (Dynamic Contrast Enhanced-MRI) in the assessment of antiangiogenic agents Phil Murphy,
2 : Closing remarks from the chairperson and end of conference Phil Murphy,
October 12, 2008 15th North American Regional Meeting - International Society for the Study of Xenobiotics Drug Induced Vascular Injury Brian R. Berridge
Can Plasma Protein Binding Represent a Safety Issue for Drug Development? The Radafaxine Case Paolo Rossato
March 25, 2008 Mastering Medicinal Chemistry Tykerb and Beyond Dirk A Heerding
March 25, 2008 Preclinical Development Advances in Liver Toxicity Testing: What’s on the Horizon? Holly L Jordan
February 19, 2008 Screening Europe Track B The Industrialisation of 1536 Well Format High Throughput Screening for Modulators of G Protein-Coupled Receptors Stuart Baddeley
November 27, 2007 Chromatin Structure & Function 2007 SIRT6 is an NAD-dependent histone deacetylase that modulates telomeric chromatin Aaron Chuang
November 12, 2007 Well Characterized Biologicals - Continuous Evolution of Chemo- and Bioanalytical Approaches Nov(12 - 14) Causes and Assessment of Product and Process-Related Impurities (13:25-18:30) Louise E. Duffy
Causes and Assessment of Product and Process-Related Impurities:Keynote Address,Current and Future Challenges of Bringing Biopharmaceuticals to Market (16:30-17:10) Louise E. Duffy
November 5, 2007 Second Annual Biomarkers Europe Nov (05-06) BIOMARKERS FOR EARLY CLINICAL TRIALS (08:00-12:15) Vincenzo Libri
BIOMARKERS FOR EARLY CLINICAL TRIALS: Biomarkers in Early Clinical Trials for Dementia (09:05-09:35) Vincenzo Libri
November 4, 2007 AACR Centennial Conference: Translational Cancer Medicine Concurrent Session 1: Clinical Pharmacogenetics: Assessing Global Diversity Eric C Lai
Concurrent Session 3: Hereditary Cancers Richard WOOSTER
October 17, 2007 Exploring Next Generation Sequencing: Applications and Case Studies (Oct 17-18) Deep Sequencing (12:00-15:30) E. Randall Lanier
Deep Sequencing: Deep Sequence of HIV RT Regions in Search of Drug Resistance Mutations in Patients Undergoing RT Inhibitor Treatment (14:05-14:35) E. Randall Lanier
October 17, 2007 Second Annual Ion Channels: An Emerging Target for Therapeutic Development Oct (17-18) TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY (09:40-12:25) Derek J. Trezise
TECHNOLOGIES FOR ION CHANNEL DRUG DISCOVERY: Novel Applications of Planar Array Electrophysiology in Ion Channel Drug Discovery (10:55-11:25) Derek J. Trezise
TARGETING PAIN MANAGEMENT: Chairperson’s Remarks (13:55-14:00) Iain Chessell
TARGETING PAIN MANAGEMENT (13:55-17:10) Iain Chessell
TARGETING PAIN MANAGEMENT: Novel and Translatable Mechanisms for Pain Treatment - Lessons From the P2X Receptor Family (14:00-14:30) Iain Chessell
October 15, 2007 2nd Annual Innovations in Clinical Trials: Implementations of Biomarkers (Oct15-16) BIOIMAGING FOR MONITORING RESPONSE TO THERAPY, DOSE SELECTION, ASSESSING MOLECULAR ACTIVITY AND RECEPTOR OCCUPANCY (08:00-13:30) Robert A. Comley
PET Receptor Occupancy - Accelerating Drug Development by Non-Invasive Measurement of Drug Action Early in the Development Pipeline (09:05-09:35) Robert A. Comley
September 30, 2007 Bridging Pharma and IT - Leveraging Information Technology to Improve Productivity (Sep30-Oct2) BRIDGING CLINICAL AND IT (10:45-15:15) Dongzhou J. Liu
BRIDGING CLINICAL AND IT: Practical Applications of Modeling and Simulation in Clinical Studies(11:30-12:30) Dongzhou J. Liu
September 24, 2007 High-Content Analysis Europe: High content Cellular Assays for compound screening and Pahtway Analysis (Sep 24-26) HCA for Mechanism-of-Action Studies: Use of the BD Pathway in CNS Drug Discovery to Determine Mechanisms of Compound Action in Primary Neuronal Cultures (16:00-16:30) Claire Scott
HCA for Mechanism-of-Action Studies (16:00-18:00) Claire Scott
About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.